International Journal of Infectious Diseases
Volume 14, Issue 9 , Pages e781-e787 , September 2010

Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice

  • Gul Ahmad

      Affiliations

    • Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, Mail Stop 6591, Lubbock, TX 79430, USA
    • ,
  • Weidong Zhang

      Affiliations

    • Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, Mail Stop 6591, Lubbock, TX 79430, USA
    • ,
  • Workineh Torben

      Affiliations

    • Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, Mail Stop 6591, Lubbock, TX 79430, USA
    • ,
  • Zahid Noor

      Affiliations

    • Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, Mail Stop 6591, Lubbock, TX 79430, USA
    • ,
  • Afzal A. Siddiqui

      Affiliations

    • Department of Microbiology and Immunology, Texas Tech University Health Sciences Center, 3601 4th Street, Mail Stop 6591, Lubbock, TX 79430, USA
    • Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 806 743 2638; fax: +1 806 743 2334.

Received 9 November 2009 ,Accepted 27 February 2010.

References 

  1. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365:1561–1569
  2. Van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop. 2003;86:125–139
  3. Siddiqui AA, Ahmad G, Damian RT, Kennedy RC. Experimental vaccines in animal models of schistosomiasis. Parasitol Res. 2008;102:825–833
  4. McManus DP, Loukas A. Current status for schistosomiasis. Clin Microbiol Rev. 2008;21:225–242
  5. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host–parasitic interactions to vaccines in clinical trials. Trends Parasitol. 2005;21:143–149
  6. Berquist NR, Leonardo LR, Mitchell GF. Vaccine linked chemotherapy: can schistosomiasis control benefit from an integrated approach?. Trends Parasitol. 2005;21:112–117
  7. Berquist NR, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis. 2008;2:e244
  8. Ahmad G, Torben W, Zang W, Matt W, Siddiqui AA. Sm-p80 based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol. 2009;31:156–161
  9. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Enhancement of Sm-p80 (largesubunit of calpain) induced protective immunity against Schistosomamansoni through co-delivery of interleukin-2 and interleukin-12 in a DNAvaccine formulation. Vaccine. 2003;21:2882–2889
  10. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Induction of protective immunityagainst Schistosoma mansoni via DNA priming with the large subunit ofcalpain (Sm-p80): Adjuvant effects of granulocyte macrophage colony stimulating factor and interleukin-4. Infect Immun. 2003;71:3844–3851
  11. Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, et al. Prime–boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by irradiated cercarial vaccine. Parasitol Res. 2009;105:1767–1777
  12. Smith JK, Siddiqui AA, Modica L, Dykes R, Simmons C, Schmidt J, et al. Interferon alpha upregulates gene expression of aquaporin-5 in cultured human parotid glands. J Interferon Cytokine Res. 1999;19:929–935
  13. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. Interleukin-21 inhibits dendritic cell activation and maturation. Blood. 2003;102:4090–4098
  14. Godinez I, Haneda T, Raffatellu M, Paixão TA, Rolán HG, Santos RL, et al. T cells help to amplify inflammatoryresponses induced by Salmonella enterica serotype Typhimurium in the intestinalmucosa. Infect Immun. 2008;76:2008–2017
  15. Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or a combination of IL-12 and IL-18. J Immunol. 2000;165:1847–1853
  16. Montgomery RA, Dallman MJ. Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction. J Immunol. 1991;147:554–560
  17. Ren F, Xhan X, Martens G, Lee J, Center D, Hanson SK, et al. Pro-IL-16 regulation in activated murine CD4+ lymphocytes. J Immunol. 2005;174:2738–2745
  18. Shen L, Zhang C, Wang T, Brooks S, Ford RJ, Lin-Lee YC, et al. Development of autoimmunity in IL-14 alphatransgenic mice. J Immunol. 2006;177:5676–5686
  19. Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, et al. Characterization of Ca(2+)-dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta. 1993;1181:37–44
  20. Silva EE, Clarke MW, Podesta RB. Characterization of a C3 receptor on the envelope of Schistosoma mansoni. J Immunol. 1993;151:7057–7066
  21. Young BW, Podesta RB. Complement and 5-HT increase phosphatidylcholine incorporation into the outer bilayers of Schistosoma mansoni. J Parasitol. 1986;72:802–803
  22. Van Hellemond JJ, Retra K, Brouwers JF, van Balkom BW, Yazdanbakhsh M, Shoemaker CB, et al. Functions of the tegument of schistosomes: clues from the proteome and lipidome. Int J Parasitol. 2006;36:691–699
  23. Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine. 1997;15:1631–1640
  24. Siddiqui AA, Pinkston JR, Quinlin ML, Kavikondala V, Rewers-Felkins KA, Phillips T, et al. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite. 2005;12:3–8
  25. Siddiqui AA, Pinkston JR, Quinlin ML, Saeed Q, White GL, Shearer MH, et al. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine. 2005;23:1451–1456
  26. Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, et al. Protective and antifecundity effects of Sm-p80 based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine. 2009;27:2830–2837
  27. Minard P, Dean DA, Jacobson RH, Vannier WE, Murrell KD. Immunization of mice with cobalt-60 irradiated Schistosoma mansoni cercariae. Am J Trop Med Hyg. 1978;27:76–86
  28. Sher A, Hieny S, James SL, Asofsky R. Mechanisms of protective immunity against Schistosoma mansoni infection in mice vaccinated with irradiated cercariae. II. Analysis of immunity in hosts deficient in T lymphocytes, B lymphocytes, or complement. J Immunol. 1982;128:1880–1884
  29. Ganley-Leal LM, Guarner J, Todd CW, Dara AA, Freeman GL, Boyer AE, et al. Comparison of Schistosoma mansoni irradiated cercariae and Sm23 DNA vaccines. Parasite Immunol. 2005;27:341–349
  30. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother. 2001;48:751–755
  31. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines. 2007;6:835–847
  32. Jankovic D, Wynn TA, Kullberg MC, Hieny S, Caspar P, James S, et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFN-gamma-dependent effector mechanisms. J Immunol. 1999;162:345–351
  33. Hewitson JP, Hamblin PA, Mountford AP. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol. 2005;27:271–280
  34. Da’dara AA, Harn DA. DNA vaccines against tropical parasitic diseases. Expert Rev Vaccines. 2005;4:575–589
  35. Da’dara AA, Lautsch N, Dudek T, Novitsky V, Lee TH, Essex M, et al. Helminth infection suppresses T-cell immune response to HIV-DNA-based vaccine in mice. Vaccine. 2006;24:5211–5219
  36. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van Cleave VH, Dunnick WA. Interleukin-12 acts as an adjuvant for humoral immunity through interferon gamma-dependent and independent mechanisms. Eur J Immunol. 1997;27:1958–1965
  37. Ward PA. The curiosity of IL-15. Nat Med 2007;8:903-4.
  38. Skundric DS, Cai J, Cruikshank WW, Gveric D. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflamm. 2006;26:13

PII: S1201-9712(10)02403-3

doi: 10.1016/j.ijid.2010.02.2266

International Journal of Infectious Diseases
Volume 14, Issue 9 , Pages e781-e787 , September 2010

Article Tools

* Image Usage & Resolution